1. Pink Sheet
  2. >>Geography
  3. >>Europe

AstraZeneca’s Brilique Triumphs As First Drug Through Germany’s New Pricing Process

 
• By Faraz Kermani

Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.

AstraZeneca PLC’s clot buster Brilique (ticagrelor) has become the first drug to emerge from the new form of pricing negotiations that were introduced in Germany as part of the law on restructuring the pharmaceutical sector (AMNOG). Despite the success of the negotiations concluded on May 31 – apparently to the satisfaction of both the manufacturer and the payer – industry remains skeptical of the system’s effectiveness.

The price secured for Brilique for the treatment of patients with acute coronary syndrome will not be revealed until the final contractual documents have been signed between the two parties – this will happen over the next few days

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.